Modulation of 5-fluorouracil with methotrexate and low-dose N- (phosphonacetyl)-L-aspartate in patients with advanced colorectal cancer. Results of a phase II study

European Journal of Cancer

Volumn 33, Issue 11, 1997, Pages 1896-1899

  Kohne C H ^a   Harstrick, A ^b   Hiddemann, W ^c   Schoffski P ^d   Wilke, H ^b   Bokemeyer, C ^e   Dorken B ^a   Schmoll, H J ^f  

^a HUMBOLDT UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e UNIVERSITY OF TÜBINGEN   (Germany)

^f MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

5 fluorouracil; Colorectal neoplasms; Hyperglycaemia; Methotrexate; PALA

Indexed keywords

FLUOROURACIL; FOLINIC ACID; METHOTREXATE; SPARFOSIC ACID;

ADULT; ADVANCED CANCER; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MALE; MUCOSA INFLAMMATION; NAUSEA; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL TIME; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARTIC ACID; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PHOSPHONOACETIC ACID; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0344333428     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)00256-6     Document Type: Article

References (21)

1. Köhne-Wömpner CH, Schmoll HJ, Harstrick A, Rustum YM. Chemotherapeutic strategies in metastatic colorectal cancer: an overview of current clinical trials. Semin Oncol 1992, 19, 105-125.
2. Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. Advanced Colorectal Cancer Meta-Analysis Project. J Clin Oncol 1994, 12, 960-969.
3. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. J Clin Oncol 1992, 10, 896-903.
4. Cadman E, Heimer R, Benz C. The influence of methotrexate pretreatment on 5-fluorouracil metabolism in L1210 cells. J Biol Chem 1981, 256, 1695-1704.
5. Cadman E, Heimer R, Davis L. Enhanced 5-fluorouracil nucleotide formation after methotrexate administration: Explanation of drug synergism. Science 1979, 205, 1135-1137.
6. Benz C, Cadman E. Modulation of 5-fluorouracil metabolism and cytotoxicity by antimetabolite pretreatment in human colorectal adenocarcinoma HCT-8. Cancer Res 1981, 41, 994-999.
7. Grem JL, King SA, O'Dwyer PJ, Leyland Jones B. Biochemistry and clinical activity of N-(phosphonacetyl)-L-aspartate: a review. Cancer Res 1988, 48, 4441-4454.
8. Martin DS, Stolfi RL, Sawyer RC, Spiegelman S, Casper ES, Young CW. Therapeutic utility of utilizing low doses of N-(phosphonacetyl)-L-aspartic acid in combination with 5-fluorouracil: a murine study with clinical relevance. Cancer Res 1983, 43, 2317-2321.
9. O'Dwyer PJ. The role of low-dose PALA in biochemical modulation. Pharmacol Ther 1990, 48, 371-380.
10. Casper ES, Vale K, Williams LJ, Martin DS, Young CW. Phase I and clinical pharmacological evaluation of biochemical modulation of 5-fluorouracil with N-(phosphonacetyl)-L-aspartic acid. Cancer Res 1983, 43, 2324-2329.
11. Marsh JC, Bertino JR, Katz KH, et al. The influence of drug interval on the effect of methotrexate and fluorouracil in the treatment of advanced colorectal cancer. J Clin Oncol 1991, 9, 371-380.
12. Sotos GA, Grogan L, Allegra CJ. Preclinical and clinical aspects of biomodulation of 5-fluorouracil. Cancer Treat Rev 1994, 20, 11-49.
13. Kemeny N, Schneider A, Martin DS, et al. Phase I trial of N-(phosphonacetyl)-L-aspartate, methotrexate, and 5-fluorouracil with leucovorin rescue in patients with advanced cancer. Cancer Res 1989, 49, 4636-4639.
14. Kemeny N, Seiter K, Martin D, et al. A new syndrome: ascites, hyperbilirubinemia, and hypoalbuminemia after biochemical modulation of fluorouracil with N-phosphonacetyl-L-aspartate (PALA). Ann Intern Med 1991, 115, 946-951.
15. Hudson MM, Dahl GV, Kalwinsky DK, Pui CH. Methotrexate plus L-asparaginase. An active combination for children with acute nonlymphocytic leukemia. Cancer 1990, 65, 2615-2618.
16. Ridgway D, Neerhout RC, Bleyer A. Attenuation of asparaginase-induced hyperglycemia after substitution of the Erwinia carotovora for the Escherichia coli enzyme preparation. Cancer 1989, 63, 561-563.
17. Peters GJ, Pinedo HM, Ferwerda W, de Graaf TW, van Dijk W. Do antimetabolites interfere with the glycosylation of cellular glycoconjugates? Eur J Cancer 1990, 26, 516-523.
18. O'Dwyer PJ, Paul AR, Walczak J, Weiner LM, Litwin S, Comis RL. Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer. J Clin Oncol 1990, 8, 1497-1503.
19. Leichman CG, Fleming TR, Muggia FM, et al. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. J Clin Oncol 1995, 13, 1303-1311.
20. O'Dwyer PJ, Ryan LM, Valone FH, et al. Phase III trial of biochemical modulation of 5-fluorouracil by iv or oral leucovorin or by interferon in advanced colorectal cancer: An ECOG/CALGB phase III trial. Proc Am Soc Clin Oncol 1996, 15, 207.
21. Fleming RA, Capizzi RL, Muss HB, et al. Phase I study of N-(phosphonacetyl)-L-aspartate with fluorouracil and with or without dipyridamole in patients with advanced cancer. Clin Cancer Res 1996, 2, 1107-1114.